• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Agora, Inc. - ADS
Micro Focus Intl PLC ADS each representing One Ord Sh
Pasqal Holding SA - Warrant
Probe Gold Inc
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Panbela Therapeutics, Inc. - Common Stock (OP:PBLA)

0.0010 UNCHANGED
Delayed Quote Updated: 10:24 AM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Panbela Therapeutics, Inc. - Common Stock

News headline image
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
October 31, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
September 24, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
July 30, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
June 24, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
June 10, 2024
Evaluation of the Safety and Efficacy of Eflornithine (Difluoromethylornithine, DFMO) in Patients with Gastric Premalignant Conditions in the High Incidence Areas of Latin American 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap